Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
investment-strategies
Blackstone's $10B Capital Opportunities V: Private Credit Reshapes the VC Exit Path
Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.
KKR's $23B North America PE Fund: Scale Capital Reshapes the Growth-Stage VC Market
Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.
Alcatraz's $50M Series B: Physical Security Is Being Rebuilt for the AI Infrastructure Era
Alcatraz's April 2026 round reflects growing demand for privacy-aware biometric access systems in critical facilities.
April 2026 NYC + U.S. VC Funding Roundup: What the Latest Deals Signal for Q2
From NYC seed activity to U.S. AI infrastructure rounds, April 2026 deal flow shows where capital is concentrating and what founders should do next.
Avo's $10M Series A: Clinical AI Is Moving Closer to Point-of-Care Decisions
Avo's April 2026 Series A highlights investor demand for AI systems that integrate directly into clinical workflows.